Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B

• Published in: Advances in therapy Vol. 41; no. 2; pp. 649 - 658
• Main Authors: Guillet, Benoit, Yan, Songkai, Hooper, Becky, Drelich, Douglass, Steenkamp, Jason, Tomic, Radovan, Mancuso, Maria Elisa
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.02.2024
• Subjects: Cardiology; Endocrinology; Factor IX - therapeutic use; Hemophilia B - complications; Hemophilia B - drug therapy; Hemorrhage - chemically induced; Hemorrhage - prevention & control; Humans; Immunoglobulin Fc Fragments - therapeutic use; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Original Research; Pharmacology/Toxicology; Recombinant Fusion Proteins - therapeutic use; Recombinant Proteins - therapeutic use; Rheumatology; Efficacy; Hemophilia B; Matching-adjusted indirect comparisons; Recombinant factor IX albumin fusion protein; Recombinant factor IX Fc fusion protein; Prophylactic treatment
• ISSN: 0741-238X; 1865-8652; 1865-8652
• DOI: 10.1007/s12325-023-02745-1

Introduction Prophylactic treatment of hemophilia B with recombinant factor IX (rFIX) molecules with enhanced pharmacokinetics including rIX-FP (albutrepenonacog alfa; Idelvion © ) and rFIXFc (eftrenonacog alfa; Alprolix © ) have commonly been used in the clinic. In the absence of head-to-head compa...